Background. Mycophenolate mofetil (MMF) is a new immune suppressive agent,
effective in the prevention of acute rejection after renal transplantation.
Methods. The study was a retrospective review of records of pediatric renal
transplant recipients from 1985 to the present.
Results. Since October 1995, the immune suppression protocol for pediatric
renal transplant recipients at Mayo Eugenio Litta Children's Hospital has i
ncluded MMF, prednisone, and cyclosporine A, During that time, 19 children
and adolescents have received renal allografts, 17 of whom were seropositiv
e for varicella antibody before transplantation, while 2 were seronegative.
Varicella infection occurred in 3 of 19 patients (15.8%), all 3 of whom ha
d serologically documented immunity to varicella virus before transplantati
on. All episodes occurred within 12 months of transplantation. All had gene
ralized vesicular lesions without dermatomal distribution. None of the pati
ents developed fever, respiratory, mucocutaneous, or central nervous system
manifestations. All were managed with oral acyclovir, and had an uncomplic
ated recovery without neuralgia, By contrast, of 74 consecutive patients tr
ansplanted before use of MMF, only 1 patient (1.4%) had varicella infection
after transplantation (P=0.026).
Conclusion. The enhanced immunosuppression achieved with MMF appears to be
associated with increased susceptibility to varicella infection.